Enliven offers a well-funded, late-stage precision-oncology opportunity with promising ELVN-001 efficacy, but its upside remains binary on Phase 3 execution against Scemblix.
Overview
Enliven Therapeutics is a pre-revenue precision-oncology biotech whose value is concentrated in ELVN-001, a selective, blood-brain-barrier-penetrant, once-daily BCR::ABL1 inhibitor for Ph+ CML. Unlike broad active-site TKIs, ELVN-001 is designed to avoid KIT, PDGFR, and SRC off-target activity while covering T315I and resistance mutations associated with allosteric therapy. Phase 1b produced **61% overall MMR and 48% MMR by week 24** in the 80 mg once-daily cohort, including comparable responses among patients who had failed Scemblix. The company has aligned with the FDA on ENABLE-2, a Phase 3 trial in 2L+ CML expected to start in the second half of 2026, with launch modeled for late 2029. Financially, Q2 2026 net loss was $32.485 million, or $(0.49) per diluted share, as operating expenses rose to $37.209 million. The offset is an unusually strong balance sheet: **$895.2 million of cash and marketable securities, zero debt, and runway into 2030** after a $460.0 million June offering. The report's five-year probability-weighted value is $89.77 per share versus a $59.32 starting price, although the outcome remains highly dependent on Phase 3 efficacy, Scemblix competition, reimbursement, and execution.